Total Credits: 0.50 including 0.50 AOA Category 1-A, 0.50 AMA PRA Category 1
Identifying Cardiac Cirrhosis
Leigh Ann Costanzo, DO
Faculty and Planning Committee Disclosures
Will be discussing off label use of Rifaximin
The Arizona Osteopathic Medical Association (AOMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. The AOMA designates this program for a maximum of 1 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician's participation.
The Arizona Osteopathic Medical Association (AOMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Arizona Osteopathic Medical Association (AOMA) designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
GRIEVANCE POLICY: The AOMA strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Uniform Guidelines and AOA Accreditation Requirements. Comments, questions, or complaints should be forwarded to AOMA Executive Director Josephine Zammuto, by calling the AOMA Office at 602-266-6699 or by mail to AOMA, 1951 W Camelback Rd, Suite 105, Phoenix, AZ 85015 or by email to email@example.com.
|Identifying Cardiac Cirrhosis - Handout|
Dr. Costanzo is a family medicine physician who graduated from A.T. Still University in Mesa and completed her residency with the Wright Center in Tucson. She has worked for Banner Medical Group since completing her training. She is also an Assistant Professor for the Family Community & Preventive Medicine program at U of A Medical School in Phoenix, a Board Member of the ACOFP-AZ and Delegate to AOMA. Dr. Costanzo incorporates osteopathic principles in the care of patients of all ages.
Dr. Costanzo discloses that she will be discussing the unlabeled/unapproved use of Rifaximin.
Please wait ...